BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Papzimeos (Zopapogene imadenovec) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Papzimeos (Zopapogene imadenovec)\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06538480-10975@assetmemo.bio
DTSTAMP:20261121T005711Z
DTSTART;VALUE=DATE:20271202
DTEND;VALUE=DATE:20271203
SUMMARY:Papzimeos (Zopapogene imadenovec): Phase 4 readout est. (NCT0653848
 0)
DESCRIPTION:Papzimeos (Zopapogene imadenovec)\, phase 4\, Recurrent Respira
 tory Papillomatosis.\nStudy: Zopa Retreatment and Vector Shedding in Adult
 s With RRP\nEstimated primary completion: 2 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/zopapogene-imadenovec#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06538480
URL:https://assetmemo.bio/drug/zopapogene-imadenovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07901738-10975@assetmemo.bio
DTSTAMP:20261121T005711Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Papzimeos (Zopapogene imadenovec): Phase 3 readout est. (NCT0790173
 8)
DESCRIPTION:Papzimeos (Zopapogene imadenovec)\, phase 3\, Recurrent Respira
 tory Papillomatosis.\nStudy: Zopapogene Imadenovec for the Treatment of Re
 current Respiratory Papillomatosis in Children\nEstimated primary completi
 on: January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zop
 apogene-imadenovec#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07901738
URL:https://assetmemo.bio/drug/zopapogene-imadenovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07756840-10975@assetmemo.bio
DTSTAMP:20261121T005711Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Papzimeos (Zopapogene imadenovec): Phase 2 readout est. (NCT0775684
 0)
DESCRIPTION:Papzimeos (Zopapogene imadenovec)\, phase 2\, Recurrent Respira
 tory Papillomatosis.\nStudy: Combination Bevacizumab and PRGN-2012 in Adul
 ts With Recurrent Respiratory Papillomatosis (RRP)\nEstimated primary comp
 letion: 1 July 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 zopapogene-imadenovec#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07756840
URL:https://assetmemo.bio/drug/zopapogene-imadenovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
